Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 3/20 | 0.34 |
| ▸ | MGLL | Q99685 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10862914 | 0.72 | ALDH1A1 (0.35) | ALDH1A1GAAFAAHMGLLLMNA | |
| SCHEMBL1072036 | 0.72 | ALDH1A1 (0.35) | ALDH1A1GAAFAAHMGLLLMNA | |
| SCHEMBL7268279 | 0.72 | ALDH1A1 (0.43) | ALDH1A1GAAFAAHMGLLLMNA | |
| SCHEMBL7651462 | 0.70 | ALDH1A1 (0.34) | ALDH1A1GAAFAAHMGLLLMNA | |
| SCHEMBL14321564 | 0.69 | ALDH1A1 (0.53) | ALDH1A1GAAFAAHMGLLLMNA | |
| SCHEMBL4103205 | 0.69 | — | — | |
| SCHEMBL1774032 | 0.69 | — | — | |
| SCHEMBL7653958 | 0.69 | — | — | |
| SCHEMBL6450361 | 0.68 | LMNA (0.34) | FAAHMGLLLMNAMEN1KMT2A | |
| SCHEMBL17371847 | 0.68 | FAAH (0.36) | FAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572355-B2 | Methods for synthesizing vinylidenes and alkenes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220017494-A1 | METHODS FOR SYNTHESIZING VINYLIDENES AND ALKENES | UNITED STATES DEPARTMENT OF ENERGY | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572355-B2 | Methods for synthesizing vinylidenes and alkenes | ALKBH2, VAV1, ALKBH3 | ALDH1A1 474/4885GAA 2463/4885FAAH 2568/4885 |
| US-20220017494-A1 | METHODS FOR SYNTHESIZING VINYLIDENES AND ALKENES | ALKBH2, VAV1, ALKBH3 | ALDH1A1 474/4885GAA 2463/4885FAAH 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.